Lexicon Pharmaceuticals (LXRX) PT Raised to $30 at Wedbush on Expected Approval after FDA Priority Review
Tweet Send to a Friend
Wedbush analyst Liana Moussatos reiterated an Outperform rating and raised her price target on Lexicon Pharmaceuticals (NASDAQ: LXRX) to $30.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
